Added to YB: 2026-06-02
Pitch date: 2026-05-29
MNKD [bullish]
MannKind Corporation
+7.45%
current return
Author Info
BioEquity Watch is a free, independent publication offering in-depth analysis of biotech and pharmaceutical companies, focused on market-relevant research, IPOs, and drug development pipelines. Sign up for the newsletter.
Company Info
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.
Market Cap
$1.4B
Pitch Price
$3.76
Price Target
8.50 (+110%)
Dividend
N/A
EV/EBITDA
43.48
P/E
-52.09
EV/Sales
4.70
Sector
Biotechnology
Category
growth
Mannkind Corp - Will today's PDUFA be a boom or a bust?
MNKD: Bullish, $8.50 PT (+134% from $3.64) via SOTP rNPV. Misread as dying diabetes co; actually diversified rare-disease play. Tyvaso DPI 10% royalty ($90M/yr) = $2.20/sh cash floor. Catalysts: Afrezza peds PDUFA May 29, Furoscix ReadyFlow PDUFA Jul 26, Nintedanib Ph1b Q3. 2025 rev $349M (+22%), $134M cash, debt-free, 2yr runway. Blue-sky $10-12; bear $1.50-2 on FDA rejection/dilution.
Read full article (8 min)